To address this challenge, to circumvent the immune and translational hurdles of MNPs, and to potentially target a broader range of drug-resistant cancers, we developed MRMI strategies to target the abundantly expressed oncoprotein extradomain-B fibronectin (EDB-FN) in the tumor extracellular matrix (ECM) 33-35. The gene discussed is FN1; the disease is cancer.